Printer Friendly
The Free Library
23,389,518 articles and books


BioSeek Initiates Compound Evaluation Collaboration with GlaxoSmithKline.

BURLINGAME, Calif., July 6 /PRNewswire/ -- BioSeek, Inc., a leader in applying integrated human biology systems for developing new therapeutics, announced today that it has entered into a collaboration agreement with GlaxoSmithKline (GSK). Under the collaboration, BioSeek will apply its BioMAP(R) Systems for the characterization of compounds from GSK.

BioSeek's BioMAP(R) Systems are a series of human primary cell-based assay systems designed to replicate the intricate cell and pathway interactions present in human disease biology. Depending on their mechanism of action, compounds induce specific patterns of changes in these systems (BioMAP profiles) that can be compared to a large number of reference profiles in BioSeek's database. BioMAP profiling can provide in-depth characterization of drug function, including defining mechanism of action and secondary activities, and can provide insights into potential clinical applications.

"We are excited to be working closely with the innovative scientific teams in GSK as we continue to demonstrate the utility of BioMAP Systems to drive drug discovery," commented Peter Staple, chief executive officer of BioSeek. "This collaboration will enable us to make use of the full range of applications of our technology."
 Financial terms of the agreement were not disclosed.

 About BioSeek



BioSeek is improving the success rate of pharmaceutical research and development by integrating human biology from the early stages of drug discovery onward. The Company's BioMAP(R) Systems incorporate predictive human cell-based disease models that generate uniquely informative activity signatures for each potential drug, driving the selection and development of new drug candidates. BioSeek is leveraging BioMAP(R) Systems technology in collaborations to enhance the productivity of its pharmaceutical partners' pipelines, and in the Company's internal programs to identify promising compounds for proprietary development in the fields of inflammation, cardiovascular diseases, autoimmune diseases and related indications.
 For more information, go to http://www.bioseekinc.com/

 Contacts:
 BioSeek, Inc.
 Peter D. Staple, Chief Executive Officer
 Tel: 650.552.0751
 E-mail: pstaple@bioseekinc.com

 MacDougall BioMedical Communications
 Kari Watson
 Tel: 508.647.0209
 E-mail: kwatson@macbiocom.com



CONTACT: Peter D. Staple, Chief Executive Officer of BioSeek, Inc., +1- 650-552-0751, pstaple@bioseekinc.com; or Kari Watson of MacDougall BioMedical Communications, +1-508-647-0209, kwatson@macbiocom.com

Web site: http://www.bioseekinc.com/
COPYRIGHT 2006 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Geographic Code:1USA
Date:Jul 6, 2006
Words:362
Previous Article:Dualstar Announces July 18 Launch of New Boys Magazine, 'Sprouse Bros. CODE'.
Next Article:Mosquito Wars: Scientists Hatch Ingenious Plots to Battle Tiny Terrorists and the Diseases They Carry -- Video Available.
Topics:

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters